GTS Securities’s Immunovant IMVT Stock Holding History

GTS Securities’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-8,600	Closed	-$362K	–	4136
2023 Q4	$362K	Sell	8,600 -117,100	-93%	-$4.31M	﹤0.01%	3052
2023 Q3	$4.83M	Buy	+125,700	New	+$2.84M	0.01%	951

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

GTS Securities's IMVT Position: Q1 2024 in Review

GTS Securities sold out of Immunovant (IMVT) in Q1 2024, closing a stake of 14,286 shares — an estimated $602K sold.

GTS Securities first reported a position in IMVT in Q4 2023 and held it in 1 quarter. The position peaked at $602K in Q4 2023. 209 funds tracked by Wall St. Rank hold IMVT as of Q1 2024.

GTS Securities reported no remaining Immunovant position as of Q1 2024 after selling out during the quarter.
GTS Securities sold 14,286 Immunovant shares in Q1 2024, an estimated $602K.
GTS Securities first reported a position in Immunovant in Q4 2023 and held it in 1 quarter.
GTS Securities's Immunovant position peaked at $602K in Q4 2023.
209 funds tracked by Wall St. Rank held Immunovant as of Q1 2024.

Based on GTS Securities's 13F filing for Q1 2024, filed 15 May 2024.